<DOC>
	<DOCNO>NCT00192101</DOCNO>
	<brief_summary>This open label , two arm , randomize , unblinded phase 2 study patient locally advance metastatic breast cancer previously treat anthracycline with/without taxane base regimen adjuvant/neoadjuvant 1st line metastatic setting . Gemcitabine administer via intravenous infusion approximately 30 minute dose 1250mg/m2 day 1 8 21-day cycle . In arm A : Cisplatin give via intravenous infusion approximately 60-120 minute dose 70 mg/m2 Day 1 21-day cycle . The investigator may attempt give Cisplatin least one liter fluid hydration outpatient basis . Patients remain study disease progression maximum six cycle administer . Study therapy may continue : - There evidence progressive disease - The patient experience unacceptable toxicity . - The investigator decide patient discontinue . - The patient request discontinuation - The patient receive 6 cycle regimen ( physician decides continue 6 cycles-this do consultation sponsor ) - Discontinuation study therapy indicate accord additional guideline describe protocol After patient discontinue study therapy , proceed post-study follow phase study .</brief_summary>
	<brief_title>Gemcitabine Plus Cisplatin Single Dose Versus Split Dose Treatment Patients With Locally Advanced Metastatic Breast Cancer After Failure Anthracyclines and/or Taxanes</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histological cytological diagnosis breast carcinoma evidence unresectable , locally recurrent , metastatic disease . Lesions amenable surgery radiation curative intent . Presence metastatic localregional recurrent disease , accord American Joint Committee Cancer Unidimensionally measurable lesion clearly define margin clearly measurable follow method accord computerized tomography ( CT ) , Chest xray clinical examination , accord RECIST criterion Patients unresectable , locally recurrent metastatic breast cancer , pretreated anthracyclines with/without taxanes ( paclitaxel , docetaxel ) contain chemotherapy either neoadjuvant/adjuvant 1st line metastatic setting enrol study . Prior chemotherapy terminate 4 week prior . Study randomization disease progression therapy document , also patient must completely recover acute chemotherapy relate toxicity ( exception alopecia ) . Prior radiotherapy must complete least 30 day study entry . Patients must recover acute toxic effect treatment prior study enrollment ( except alopecia ) . Lesions radiate included site measurable disease unless clear tumor progression document lesion since end radiation therapy . Have receive treatment within last 30 day investigational drug indication study entry . Concurrent administration tumor therapy , include cytotoxic chemotherapy , surgery cancer , radiotherapy , hormonal therapy immunotherapy ( include Herceptin ) Active infection opinion investigator would compromise patient 's ability tolerate therapy , unless adequately treat . Serious concomitant disorder would compromise safety patient compromise patient 's ability complete study , discretion investigator . Second primary malignancy clinically detectable time consideration study enrollment ( except situ carcinoma cervix adequately treat basal cell carcinoma skin )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>